ALKS

Alkermes plc Press Releases

$44.94
*  
0.77
1.68%
Get ALKS Alerts
*Delayed - data as of Jul. 25, 2014  -  Find a broker to begin trading ALKS now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results
7/24/2014 4:00:00 PM - Business Wire

Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis
7/17/2014 7:00:00 AM - Business Wire

Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates
7/9/2014 7:00:00 AM - Business Wire

Alkermes Presents Phase 3 Data From Successful Pivotal Study of Aripiprazole Lauroxil for Treatment of Schizophrenia at ASCP Annual Meeting
6/18/2014 7:00:00 AM - Business Wire

Biotech Stocks Technical Data -- Research on Navidea Biopharma, Alkermes, Nanosphere, and Organovo Holdings
6/10/2014 8:00:00 AM - PR Newswire

Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461 for Treatment of Major Depressive Disorder
6/10/2014 7:00:00 AM - Business Wire

Alkermes to Present Data on New Medicines in Development for Schizophrenia and Depression at Upcoming American Society of Clinical Psychopharmacology Annual Meeting
6/3/2014 7:00:00 AM - Business Wire

Alkermes Announces Initiation of Second Phase 2 Clinical Study of ALKS 3831, a Novel Broad-Spectrum Oral Antipsychotic
6/2/2014 7:00:00 AM - Business Wire

Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences
5/27/2014 4:00:00 PM - Business Wire

Alkermes’ Corporate Presentation to be Webcast at the UBS Global Healthcare Conference
5/12/2014 4:00:00 PM - Business Wire

Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma
5/9/2014 1:30:00 PM - PR Newswire

Alkermes plc Reports First Quarter 2014 Financial Results
4/30/2014 7:00:00 AM - Business Wire